pISSN 1226-6051
eISSN 2508-786X
eISSN 2508-786X
Characteristics of included studies and patient demographic data in this study (warfarin)
| Study | Study design | Country | Type of VKAs | Note | N (M/F) | Age (years) | BMI (kg/m2) or BW (kg) | Indication of VKAs, n (%) | HWE | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DVT | PE | AF | HVP | Others | |||||||||
| Campos EIF et al. 2018 |
Cross-sectional | Brazil | Warfarin | Conference abstract | 136 (58/78) | 60.1 ± 13.6 | - | - | - | 98 (72.1) | - | - | - |
| de Oliveira Almeida VC et al. 2014 |
Prospective cohort | Brazil | Warfarin | - | 116 (40/76) | 42.3 ± 14.5 | 27.3 ± 5.2 kg/m2 | 94 (81) | 20 (17) | - | - | 14 (12) | 0.038 |
| Ferrari M et al. 2014 | Case-control | Italy | Warfarin | - | 66 (34/32) | 76.8 ± 6.6 | 26.4 ± 4.1 kg/m2 | - | - | 54 (81.8) | 12 (18.2) | - | 0.13 |
| Issac MS et al. 2014 |
Cohort | Egypt | Warfarin | - | 84 (41/43) | 40.9 ± 13.3 | 79.16 ± 21.33 kg | 12 (14.2) | - | 5 (6) | - | 67 (79.8) | 0.216 |
| Kim Y et al. 2013 |
- | USA | Warfarin | European Americans | 74 (59/15) | 58.2 ± 10.9 | 97.5 ± 27.2 |
17 (23.0) | 14 (18.9) | 27 (36.5) | 5 (6.8) | 11 (14.9) | 0.926 |
| African Americans | 59 (38/21) | 55.7 ± 11.3 | 95.2 ± 23.1 kg | 14 (23.7) | 14 (23.7) | 16 (27.1) | 6 (10.2) | 9 (15.3) | 0.33 | ||||
| Hispanic Americans | 42 (23/19) | 53.8 ± 16.5 | 85.9 ± 21.9 kg | 9 (21.4) | 6 (14.3) | 14 (33.3) | 5 (11.9) | 8 (19.0) | 0.183 | ||||
| Asian Americans | 21 (13/8) | 58.1 ± 9.9 | 78.9 ± 17.5 |
3 (14.3) | 1 (4.8) | 8 (38.1) | 5 (23.8) | 4 (19.0) | 0.924 | ||||
| Total | 196 (133/63) | - | - | 43 (21.9) | 35 (17.9) | 65 (33.2) | 21 (10.7) | 32 (16.3) | - | ||||
| Li W et al. 2020 |
- | China | Warfarin | - | 214 (113/101) | 72.6 ± 11.2 | 24.0 ± 3.9 kg/m2 | 3 (1.4) | 12 (5.6) | 165 (77.1) | - | 34 (15.9) | >0.05 |
| Tavares LC et al. 2018 |
Retrospective study | Brazil | Warfarin | Total | 309 (155/154) | 64 ± 14 | 27 ± 5 kg/m2 | - | - | - | - | - | 0.899 |
| Wadelius M et al. 2004 | Case-control | Sweden | Warfarin | - | 201 (135/66) + 24 |
66.9 (28-88) | - | 9 (4.5) | 113 (56.2) | 49 (24.4) | 13 (6.5) | >0.05 | |
| Gschwind L et al. 2015 |
Prospective observational | Swiss | Acenocoumarol | Caucasians (n=109) Africans (n=6) |
115 (62/53) | 63.2 ± 18.2 | - | 70 (60.9) | 29 (25.2) | - | 16 (13.9) | >0.05 | |
| Jiménez -Varo E et al. 2014 |
Retrospective observational | Spain | Acenocoumarol | Algorithm cohort | 134 (75/59) | 73 ± 10 | 29 [27-33] kg/m2 | - | - | 109 (81.3) | - | 25 (18.7) | 0.530 |
| Validation cohort | 30 (16/14) | 73 ± 8 | 32 ± 5.7 kg/m2 | - | - | 26 (86.7) | - | 4 (13.3) | |||||
| Total | 164 (89/75) | 73 ± 9 | 30 [27-33] kg/m2 | - | - | 135 (82.3) | - | 29 (17.7) | |||||
| Rojo M et al. 2020 | Retrospective cohort | Chile | Acenocoumarol | - | 279 (152/127) | 66.49 ± 14.11 | 29.32 ± 5.77 kg/m2 | - | - | - | - | - | <0.05 |
| Saraeva RB et al. 2007 | - | Bulgaria | Acenocoumarol | - | 96 (56/40) | 60 ± 12 (17-86) | 80 ± 15 kg | 6 (6.3) | 11 (11.5) | 27 (28.1) | 40 (41.7) | 12 (12.5) | >0.05 |
| Sychev DA et al. 2016 |
Retrospective cohort | Russia | Acenocoumarol | - | 50 (34/16) | 59 ± 8 | 85.7 ± 11.3 kg | - | - | - | - | - | 0.94 |
aTwenty-four additional patients with serious warfarin bleeding were recruited (20 through the Swedish spontaneous reporting of adverse drug reactions and 4 from an ongoing national study on cerebral bleeding and warfarin); *